New Launch12 Feb 2025, 02:36 pm
Glenmark Pharmaceuticals Inc., USA Launches Clindamycin Phosphate Foam, 1% with Annual Sales of $5.8 Million
AI Summary
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the launch of Clindamycin Phosphate Foam, 1%. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin® Foam, 1%, of Mylan Pharmaceuticals Inc. As per IQVIA™ sales data for the 12-month period ending December 2024, the Evoclin® Foam, 1% market achieved annual sales of approximately $5.8 million.*
Key Highlights
- Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%
- Bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin® Foam, 1%
- Evoclin® Foam, 1% market achieved annual sales of approximately $5.8 million as per IQVIA™ sales data
- Glenmark's Green House Gas (GHG) emission reduction targets approved by the Science Based Target initiative (SBTi)